Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2024 16:05 ET | Source: Theriva Biologics, Inc.

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...
October 16, 2024 16:29 ET | Source: Theriva Biologics, Inc.

Theriva Biologics anuncia la designación de medicamento huérfano concedida por la Comisión Europea al VCN-01 para el tratamiento del retinoblastoma

ROCKVILLE, Maryland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa de fase clínica que desarrolla terapias diseñadas para tratar...
October 16, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and...
October 03, 2024 20:05 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics anuncia el resultado positivo de la revisión del Comité de vigilancia y seguridad de los datos en el ensayo clínico de Fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas

ROCKVILLE, Maryland, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), («Theriva» o la «Compañía»), una empresa diversificada de fase clínica que desarrolla terapias...
October 03, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

ROCKVILLE, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed...
September 26, 2024 21:06 ET | Source: Theriva Biologics, Inc.

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed...
September 23, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics logra el objetivo de inscripción de pacientes en VIRAGE, el ensayo de Fase 2b de VCN-01 con gemcitabina/nab-paclitaxel para el tratamiento del cáncer de páncreas metastásico

- Objetivo de 92 pacientes evaluables (46 en la rama de control y 46 en la rama de tratamiento con VCN-01) inscritos en 15 centros de España y EE. UU. en un plazo de 21 meses – ROCKVILLE, Maryland,...
September 23, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months – ROCKVILLE, Md., Sept. 23, 2024 (GLOBE...
September 16, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program

ROCKVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) a diversified clinical-stage company developing therapeutics designed to...
September 16, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics obtiene financiación para la fabricación del plan nacional de transferencia de conocimiento del Gobierno español

ROCKVILLE, Maryland, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX) («Theriva» o la «Empresa»), una empresa diversificada de fase clínica que desarrolla terapias...